These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19092251)

  • 1. Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.
    Binder S; Deuschl G; Volkmann J
    Eur Neurol; 2009; 61(3):149-53. PubMed ID: 19092251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings.
    Spieker S; Löschmann P; Jentgens C; Boose A; Klockgether T; Dichgans J
    Clin Neuropharmacol; 1995 Jun; 18(3):266-72. PubMed ID: 8635185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actigraphy monitoring of symptoms in patients with Parkinson's disease.
    Pan W; Kwak S; Li F; Wu C; Chen Y; Yamamoto Y; Cai D
    Physiol Behav; 2013 Jul; 119():156-60. PubMed ID: 23748129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
    Katayama S
    Eur Neurol; 2001; 46 Suppl 1():11-7. PubMed ID: 11741098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tremor in Parkinson's disease: 24-hr monitoring with calibrated accelerometry.
    Thielgen T; Foerster F; Fuchs G; Hornig A; Fahrenberg J
    Electromyogr Clin Neurophysiol; 2004; 44(3):137-46. PubMed ID: 15125053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unilateral caudal zona incerta deep brain stimulation for Parkinsonian tremor.
    Blomstedt P; Fytagoridis A; Åström M; Linder J; Forsgren L; Hariz MI
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1062-6. PubMed ID: 22709794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
    Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M
    Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicophysiological study of tremor in Parkinson's disease: quantitative tremor-based assessment of motor count using actigraphy].
    Mochio S; Oka H; Katayama K; Sato H
    Nihon Rinsho; 1997 Jan; 55(1):158-62. PubMed ID: 9014442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linear and nonlinear tremor acceleration characteristics in patients with Parkinson's disease.
    Meigal AY; Rissanen SM; Tarvainen MP; Georgiadis SD; Karjalainen PA; Airaksinen O; Kankaanpää M
    Physiol Meas; 2012 Mar; 33(3):395-412. PubMed ID: 22370008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
    Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.